Should I Buy DDS? DDS 2026 Analysis

Should You Buy Dillard's Inc (DDS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

666.510

1 Day change

4.88%

52 Week Range

741.980

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price is closer to resistance than support, momentum is positive but getting stretched, and near-term upside looks limited versus downside to the next supports.
Best setup would be on a pullback toward the pivot (~~636) or stronger support zones (~~604 / ~584); at the current ~643, the risk/reward is not compelling.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: Entry signal triggered on 2026-02-02; price is only +1.28% since, so the swing is still in progress, but the current entry is less attractive than at signal time.
No news-driven catalyst this week; the next notable event risk/catalyst is earnings (2026-02-24 pre-market).

Technical Analysis

Trend/Momentum: MACD histogram is positive (0.183) and expanding, supporting a continued bullish bias in the near term.
RSI: RSI(6) at ~67.8 is high-neutral/near overbought, suggesting upside may be harder to extend cleanly without consolidation.
Moving averages: Converging MAs indicate the trend is not strongly directional long-term; current move looks more like a momentum push than a structurally strong trend.
Levels:
- Pivot: ~636.5 (current price ~643 is slightly above—bullish but not extended)
- Resistance: R1 ~669.0, R2 ~689.0 (near-term upside areas)
- Support: S1 ~604.1, S2 ~584.1 (meaningful downside if momentum fades)
Short-horizon pattern stats provided: modeled probabilities imply modest upside (next day ~~+0.97%, week ~+2.27%) with a better month expectancy (~~+9.09%), but the current location near resistance reduces immediate entry appeal.

Positive Catalysts

and price has not run far yet (+1.28%), implying the swing thesis could still be active.

Neutral/Negative Catalysts

than to strong support, making the immediate risk/reward less favorable for a fresh buy.

Financial Performance

Latest quarter: 2026/Q3
Revenue: $1.491B, +2.74% YoY (modest top-line growth).
Net income: $129.81M, +4.18% YoY (profit growth slightly outpacing sales).
EPS: $8.31, +7.50% YoY (benefiting from operating leverage and/or share count effects).
Gross margin: 41.25%, +1.83% YoY (margin improvement is a positive, but still consistent with “modest growth” narrative overall).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Trend in recent changes: price targets were raised across the board after Q3, but ratings remain mostly cautious.
2025-11-28 UBS: PT raised to $460 (from $184), Sell; views earnings growth potential as very limited (low-single-digit sales, flattish margins).
2025-11-25 JPMorgan: PT raised to $524 (from $411), Underweight.
2025-11-14 Telsey: PT raised to $700 (from $550), Market Perform; cites disciplined execution and consistent performance.
Wall Street pro view (pros/cons):
- Pros: execution discipline, consistent beats, modest sales growth, some margin improvement.
- Cons: limited long-term earnings growth runway implied by low growth + margin constraints; two major shops still negative on rating despite higher PTs.

2 Analyst Rating

Wall Street analysts forecast DDS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DDS is 492 USD with a low forecast of 460 USD and a high forecast of 524 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

2 Sell

Moderate Sell

Current: 635.510

Low

460

Averages

492

High

524

Current: 635.510

Low

460

Averages

492

High

524

UBS

Mauricio Serna

Sell

maintain

$184 -> $460

AI Analysis

2025-11-28

Reason

UBS

Mauricio Serna

Price Target

$184 -> $460

AI Analysis

2025-11-28

maintain

Sell

Reason

UBS analyst Mauricio Serna raised the firm's price target on Dillard's to $460 from $184 and keeps a Sell rating on the shares. The firm updated the company's model post the Q3 report. Dillard's "is adept to drive modest sales growth," the analyst tells investors in a research note. However, UBS sees "very limited" earnings growth potential for Dillard's given its low-single-digit sales growth and flattish margins.

JPMorgan

Matthew Boss

maintain

$411 -> $524

2025-11-25

Reason

JPMorgan

Matthew Boss

Price Target

$411 -> $524

2025-11-25

maintain

Reason

JPMorgan analyst Matthew Boss raised the firm's price target on Dillard's to $524 from $411 and keeps an Underweight rating on the shares. The firm updated the company's model post the Q3 report.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DDS

Unlock Now

DDS Should I Buy

DDS Should I Buy

Should You Buy Dillard's Inc (DDS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch